Search research articles
Contact Us
Filters
Showing results (521-530 of 740) with videos related to
Page
of 74
Sort By:
JMIR Mhealth and Uhealth
|
December 16, 2020
ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study
Xueliang Hua, Chen Li, Jason M Pogue, et al.
British Journal of Cancer
|
November 21, 1998
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion
L Paz-Ares, R Kunka, D DeMaria, et al.
Antimicrobial Agents and Chemotherapy
|
March 10, 2010
Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system
Tara Reddy, Teena Chopra, Dror Marchaim, et al.
Infection Control and Hospital Epidemiology
|
September 5, 2020
Institutional quality and patient safety programs: An overview for the healthcare epidemiologist
Pranavi V Sreeramoju, Tara N Palmore, Grace M Lee, et al.
The Journal of Antimicrobial Chemotherapy
|
January 29, 2019
The hypothetical impact of Accelerate Pheno™ system on time to effective therapy and time to definitive therapy in an institution with an established antimicrobial stewardship programme currently utilizing rapid genotypic organism/resistance marker identification
Oryan Henig, Christopher C Cooper, Keith S Kaye, et al.
Arthritis Research & Therapy
|
March 4, 2010
Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement
Andrew D Cook, Christine M De Nardo, Emma L Braine, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE
|
January 30, 2023
At the vanguard: Leaders' perspectives on establishing healthcare system infection prevention programs
Michael P Stevens, Sharon B Wright, Keith S Kaye, et al.
Antimicrobial Agents and Chemotherapy
|
April 24, 2004
Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States
Keith S Kaye, Howard S Gold, Mitchell J Schwaber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 9, 2017
Electronically Available Comorbidities Should Be Used in Surgical Site Infection Risk Adjustment
Sarah S Jackson, Surbhi Leekha, Laurence S Magder, et al.
Antimicrobial Agents and Chemotherapy
|
February 26, 2020
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections
Keith S Kaye, Helen W Boucher, Michelle L Brown, et al.
Page
of 74
Search research articles
Search
Showing results (521-530 of 740) with videos related to
Sort By:
Page
of 74
JMIR Mhealth and Uhealth
|
December 16, 2020
ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study
Xueliang Hua, Chen Li, Jason M Pogue, et al.
British Journal of Cancer
|
November 21, 1998
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion
L Paz-Ares, R Kunka, D DeMaria, et al.
Antimicrobial Agents and Chemotherapy
|
March 10, 2010
Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system
Tara Reddy, Teena Chopra, Dror Marchaim, et al.
Infection Control and Hospital Epidemiology
|
September 5, 2020
Institutional quality and patient safety programs: An overview for the healthcare epidemiologist
Pranavi V Sreeramoju, Tara N Palmore, Grace M Lee, et al.
The Journal of Antimicrobial Chemotherapy
|
January 29, 2019
The hypothetical impact of Accelerate Pheno™ system on time to effective therapy and time to definitive therapy in an institution with an established antimicrobial stewardship programme currently utilizing rapid genotypic organism/resistance marker identification
Oryan Henig, Christopher C Cooper, Keith S Kaye, et al.
Arthritis Research & Therapy
|
March 4, 2010
Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement
Andrew D Cook, Christine M De Nardo, Emma L Braine, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE
|
January 30, 2023
At the vanguard: Leaders' perspectives on establishing healthcare system infection prevention programs
Michael P Stevens, Sharon B Wright, Keith S Kaye, et al.
Antimicrobial Agents and Chemotherapy
|
April 24, 2004
Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States
Keith S Kaye, Howard S Gold, Mitchell J Schwaber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 9, 2017
Electronically Available Comorbidities Should Be Used in Surgical Site Infection Risk Adjustment
Sarah S Jackson, Surbhi Leekha, Laurence S Magder, et al.
Antimicrobial Agents and Chemotherapy
|
February 26, 2020
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections
Keith S Kaye, Helen W Boucher, Michelle L Brown, et al.
Page
of 74